Individualizing treatment of refractory and relapsed ITP in adults and its development of study.
- Author:
Yu HUANG
1
;
Wei LI
;
Bo YANG
;
Hong-Li ZHU
;
Yan-Hui DANG
Author Information
1. Department of Geriatric Hematology, Chinese PLA General Hospital, Beijing 100853, China; Tumor Center of the First Hospital of Jilin University, Changchun 130021, Jilin Province, China.
- Publication Type:Journal Article
- MeSH:
Adult;
Humans;
Precision Medicine;
methods;
Purpura, Thrombocytopenic, Idiopathic;
therapy;
Recurrence
- From:
Journal of Experimental Hematology
2009;17(6):1609-1615
- CountryChina
- Language:Chinese
-
Abstract:
Idiopathic thrombocytopenic purpura (ITP) is a common hematological disease. It bleeds with peripheral blood platelet reduction as the main clinical manifestation, and manifests a chronic history in adult people. 11% - 35% ITP patients develop into a refractory course, which may be related with gene polymorphisms. There is currently no consensus on how best to manage refractory/relapsed ITP. In part, this reflects the need for individualized treatment due to the patients' requirements and their responsiveness to therapies. The objective of this review is to provide a clinically useful guide to current management strategies. This article summarizes all the treatment for refractory ITP, and highlights new therapies, including the anti-CD20 antibody, thrombopoietic agents, TPO receptor agonist and HSCT. The pancytoprotector shows good effect in the treatment of refractory and relapsed ITP in China. In a word, to give different treatments individually is most important.
